Filter Results

Clinical Studies

Open

  • ALSENLITE: An Open-label Pilot Study of Senolytics for Alzheimer's Disease (ALSENLITE) Rochester, Minn.

    The purpose of this study is to measure target engagement in cerebrospinal fluid (CSF) and blood, and to establish the feasibility and safety of Dasatinib plus Quercetin treatment in adults with early stage but symptomatic Alzheimer's Disease (AD) to inform and select the best blood, CSF, urine, and other analyses to conduct in banked samples from a larger Phase 2b clinical trial.

  • Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol (ADNI3) Rochester, Minn., Jacksonville, Fla.

    Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease (AD). The overall goal of the study is to continue to discover, optimize, standardize, and validate clinical trial measures and biomarkers used in AD research.

  • Cerebrospinal Fluid (CSF) Biomarkers for Prediction of Dementia Rochester, Minn.

    To further investigate biomarkers in CSF as possible predictors for mild cognitive impairment and dementia

  • Electronic Validation of Online Methods to Predict and Monitor Cognitive Decline (e-VAL) (e-VAL) Rochester, Minn.

    The goal of this project is to assess the validity and efficacy of online methods to predict and monitor cognitive and functional decline in elders with normal cognition (CN), subjective memory complaints (SMC), and mild cognitive impairment (MCI) using electronic versions of the Clinical Dementia Rating Scale (CDR) and the Financial Capacity Instrument-Short Form (FCI-SF). We will validate the e-instruments by implementing them within the Brain Health Registry (BHR, CHR #12-09628), and comparing online data obtained unsupervised at home with online data obtained while supervised in research clinics, over the telephone, or by video technology from participants followed longitudinally for 4 years and across 4 sites. In addition to the newly-developed electronic CDR (eCDR) and electronic FCI (eFCI), we will use BHR data, including the Cogstate Brief Battery and additional self-report questionnaires, to determine whether these electronic instruments can both measure and predict cognitive and functional decline. We also intend to determine the ability of electronic instruments to predict ß-amyloid (Aß) PET positivity. The development and validation of scalable, accessible screening tools, such as online electronic instruments, will likely lead to improved methods that can be used in clinical trials and multiple healthcare settings to identify people at risk for and undergoing cognitive and functional decline and Alzheimer’s disease (AD), ultimately leading to prevention of AD and improved healthcare for neurodegenerative disorders.

Closed for Enrollment

  • Cerebrospinal Fluid (CSF) Biomarkers for Prediction of Dementia Jacksonville, Fla.

    To further investigate biomarkers in CSF as possible predictors for mild cognitive impairment and dementia

  • MarkVCID Validation in the General Community (MarkVCID2) Rochester, Minn., Jacksonville, Fla.

    The purpose of this study is to evaluate and compare the clinical usefulness of plasma and MRI-based MarkVCID biomarkers in relation to age, sex, systemic vascular health, race, ethnicity and cognition.

  • Mayo Alzheimer's Disease Research Center Jacksonville, Fla., Rochester, Minn.

    This study is being done to learn more about normal memory and aging, mild memory and thinking problems, Alzheimer's disease and other forms of dementia.

  • Mayo Clinic Olmsted Study of Aging (Expansion Cohort) Rochester, Minn.

    The purpose of this study is to learn more about using a computerized test in your home to study how memory changes with age, mild memory and thinking problems and Alzheimer's disease and other forms of dementia. This study will help us determine how often memory problems occur in people in our community, and help to identify factors that may influence changes in memory and thinking skills.

  • Mayo Clinic Olmsted Study of Aging (MCSA) Rochester, Minn.

    This study is being done to learn more about normal memory and aging, mild memory and thinking problems, Alzheimer's disease and other forms of dementia. This study will help us determine how often memory problems occur in people in our community, and help to identify factors that may influence changes in memory and thinking skills.

.